

**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**  
**Pursuant to Rule 13a-16 or 15d-16 under**  
**the Securities Exchange Act of 1934**

For the month of: July 2016

Commission File Number: 001-35776

---

**ACASTI PHARMA INC.**  
(Name of Registrant)

---

**545 Promende du Centropolis**  
**Suite 100**  
**Laval, Québec**  
**Canada H7T 0A3**  
(Address of Principal Executive Office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

---

This Report on Form 6-K including the exhibits hereto shall be deemed to be incorporated by reference into Acasti Pharma Inc.'s registration statement on Form S-8 (File No. 333-191383) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**ACASTI PHARMA INC.**

Date: July 14, 2016

By: /s/ Mario Paradis  
Name: Mario Paradis  
Title: VP & Chief Financial Officer

---

## EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	Acasti Report on the Voting Results

**VIA SEDAR**

July 14, 2016

**Autorité des marchés financiers**  
**Alberta Securities Commission**  
**British Columbia Securities Commission**  
**Manitoba Securities Commission**  
**Ontario Securities Commission**

Subject: Acasti Pharma inc. (the "Corporation")  
 Report on the Voting Results, in accordance with article 11.3 of *Regulation 51-102 respecting Continuous Disclosure Obligations* ("Regulation 51-102")

Following the annual and special meeting of shareholders of the Corporation held on July 12, 2016 (the "AGM"), this report presents the items voted on during the AGM and the corresponding voting results, in accordance with article 11.3 of Regulation 51-102. For more detailed information on the proposals submitted to shareholders, please refer to the Proxy Management Circular of the Corporation dated June 14, 2016 (the "Circular").

According to the scrutineers reports, being present in person or by proxy, were the holders of 6,693,736 common shares, or 62.49%, of the 10,712,038 common shares issued and outstanding on May 31, 2016, the record date for the AGM.

**1. Election of the directors of the Corporation for the ensuing year**

	<b>Votes in Favor</b>	<b>% In Favor</b>	<b>Votes Withheld</b>	<b>% Withheld</b>
Jean-Marie (John) Canan	5,592,689	99.79%	11,738	0.21%
Roderick N. Carter	5,592,417	99.79%	12,010	0.21%
Janelle D'Alvise	5,597,512	99.88%	6,915	0.12%
James S. Hamilton	5,596,128	99.85%	8,299	0.15%
Leendert H. Staal	5,597,562	99.88%	6,865	0.12%

**2. Appointment of KPMG LLP as auditors for the ensuing year and to authorize the directors of the Corporation to fix their remuneration**

<b>Votes in Favor</b>	<b>% In Favor</b>	<b>Votes Withheld</b>	<b>% Withheld</b>
6,602,471	99.38%	41,208	0.62%

3. Ordinary resolution to approve certain amendments to the Corporation's stock option plan, as previously approved by the board of directors of the Corporation (the "Board"), as more particularly described in the accompanying Circular

Votes in Favor	% In Favor	Votes Against	% Against
5,437,680	98.88%	61,850	1.12%

4. Ordinary resolution to approve the grant of 525,000 options to purchase common shares of the Corporation, as previously approved by the Board, as more particularly described in the Circular

Votes in Favor	% In Favor	Votes Against	% Against
5,549,295	99.02%	55,132	0.98%

5. Ordinary resolution to approve certain amendments to the Corporation's equity incentive plan, as more particularly described in the Circular

Votes in Favor	% In Favor	Votes Against	% Against
5,440,251	98.92%	59,279	1.08%

Sincerely,

/s/ Jean-Daniel Bélanger

Jean-Daniel Bélanger

Director, Corporate Affairs and Corporate Secretary